Discoidin-Domain-Receptor-Inhibitors-Modulators-MCE.docx 免費(fèi)下載
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、 HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html Discoidin HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html Domain HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html HYPERL
2、INK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html ReceptorDiscoidin domain receptors (DDRs) are members of the transmembrane receptor tyrosine kinase (RTK) superfamily which aredistinguished from others by the presence of a discoidin motif in the extracellular domain and their utilizati
3、on of collagens asinternal ligands. Two types of DDRs, DDR1 and DDR2, have been identified with distinct expression profiles and ligand specificities.Upon collagen binding, DDRs transduce cellular signaling involved in various cell functions, including cell adhesion, proliferation,differentiation, m
4、igration, and matrix homeostasis. Altered DDR function resulting from either mutations or overexpression hasbeen implicated in several types of disease, including atherosclerosis, inflammation, cancer, and tissue fibrosis. DDRs have beenconsidered as novel potential molecular targets for drug discov
5、ery and increasing efforts are being devoted to the identification ofnew small molecule inhibitors targeting the receptors.www.MedChemE 1 HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html Discoidin HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html HYPERLINK http
6、s:/www.MedChemE/Targets/Discoidin Domain Receptor.html Domain HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html Receptor HYPERLINK https:/www.MedChemE/Targets/Discoidin Domain Receptor.html HYPERLINK https:/www.M
7、edChemE/Targets/Discoidin Domain Receptor.html Inhibitors HYPERLINK https:/www.MedChemE/DDR1-IN-2.html 7rh(DDR1-IN-2) Cat. No.: HY-U00444 HYPERLINK https:/www.MedChemE/DDR_Inhibitor.html DDR HYPERLINK https:/www.MedChemE/DDR_Inhibitor.html HYPERLINK https:/www.MedChemE/DDR_Inhibitor.html InhibitorCa
8、t. No.: HY-W0189317rh (DDR1-IN-2) is a potent inhibitor of discoidindomain receptor 1 (DDR1), with an IC of 13.150nM, and also less potently inhibits DDR2, with anIC of 203 nM.50DDR Inhibitor is a potent discoidin domain receptor(DDR) inhibitor, with an IC of 3.3 nM for DDR2,50and shows 53% inhibiti
9、on on DDR1 at 1.5 nM.Purity: 98.62%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mgPurity: 99.43%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg HYPERLINK https:/www.MedChemE/DDR1-IN-3.html DDR-TRK-1 HYPERLINK https:/www.MedChemE/DDR1-IN-3.html HYPERLINK
10、 https:/www.MedChemE/DDR1-IN-1.html DDR1-IN-1Cat. No.: HY-100695 Cat. No.: HY-13979DDR-TRK-1 is a selective Discoidin Domain Receptor1 (DDR1) inhibitor, with an IC value of 9.4 nM.50DDR-TRK-1 also inhibits TRK family.DDR1-IN-1 is a potent and selective DDR1 receptortyrosine kinase inhibitor with an
11、IC of 105 nM;504-fold less potent for DDR2 (IC = 413 nM).50Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.20%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/ddr1-in-1-dihydrochloride.html DDR1-IN-1 HYPERLIN
12、K https:/www.MedChemE/ddr1-in-1-dihydrochloride.html HYPERLINK https:/www.MedChemE/ddr1-in-1-dihydrochloride.html dihydrochloride HYPERLINK https:/www.MedChemE/ddr1-in-1-dihydrochloride.html HYPERLINK https:/www.MedChemE/ddr1-in-4.html DDR1-IN-4Cat. No.: HY-13979A Cat. No.: HY-114173DDR1-IN-1 dihydr
13、ochloride is a potent andselective DDR1 receptor tyrosine kinase inhibitorwith an IC of 105 nM; 4-fold less potent for50DDR2 (IC = 413 nM).50DDR1-IN-4 (Compound 2.45) is a selective andpotent Discoidin Domain Receptor 1 (DDR1)autophosphorylation inhibitor, with IC values of5029 nM and 1.9 M for DDR1
14、 and DDR2, respectively.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.01%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/ddr1-in-5.html DDR1-IN-5 HYPERLINK https:/www.MedChemE/ddr1-in-5.html HYPERLINK https:/ww
15、w.MedChemE/ddr1-in-6.html DDR1-IN-6Cat. No.: HY-133669 Cat. No.: HY-133670DDR1-IN-5 is a selective Discoidin Domain Receptorfamily, member 1 (DDR1) inhibitor with an IC of507.36 nM. DDR1-IN-5 inhibits auto-phosphorylationDDR1b (Y513) with an IC of 4.1 nM. DDR1-IN-5 has50anti-cancer activity.DDR1-IN-
16、6 is a selective Discoidin Domain Receptorfamily, member 1 (DDR1) inhibitor with an IC of509.72 nM. DDR1-IN-6 inhibits auto-phosphorylationDDR1b (Y513) with an IC of 9.7 nM. DDR1-IN-6 has50anti-cancer activity.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data:
17、 No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/ddr2-in-1.html DDR2-IN-1 HYPERLINK https:/www.MedChemE/ddr2-in-1.html HYPERLINK https:/www.MedChemE/fgfr1-ddr2-inhibitor-1.html FGFR1/DDR2 HYPERLINK https:/www.MedChemE/fgfr1-ddr2-inhibitor-1.html HYPERLINK https:/www.MedChemE/fg
18、fr1-ddr2-inhibitor-1.html inhibitor HYPERLINK https:/www.MedChemE/fgfr1-ddr2-inhibitor-1.html HYPERLINK https:/www.MedChemE/fgfr1-ddr2-inhibitor-1.html 1Cat. No.: HY-112545 Cat. No.: HY-114311DDR2-IN-1 is potent DDR2 inhibitor with an IC50of 26 nM. DDR2-IN-1, compound 129, can be used forosteoarthri
19、tis research.FGFR1/DDR2 inhibitor 1 is an orally activeinhibitor of fibroblast growth factor receptor 1(FGFR1) and discoindin domain receptor 2 (DDR2),with IC values of 31.1 nM and 3.2 nM,50respectively. Antitumor activity.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 99.0
20、3%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/LY2801653.html Merestinib(LY2801653) Cat. No.: HY-15514 HYPERLINK https:/www.MedChemE/LY2801653-dihydrochloride.html Merestinib HYPE
21、RLINK https:/www.MedChemE/LY2801653-dihydrochloride.html HYPERLINK https:/www.MedChemE/LY2801653-dihydrochloride.html dihydrochloride(LY2801653 dihydrochloride) Cat. No.: HY-15514AMerestinib (LY2801653) is a potent, orallybioavailable c-Met inhibitor (K=2 nM) withianti-tumor activities.Merestinib di
22、hydrochloride (LY2801653dihydrochloride) is a potent, orally bioavailablec-Met inhibitor (K=2 nM) with anti-tumoriactivities.Purity: 99.99%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 99.36%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK http
23、s:/www.MedChemE/ml786-dihydrochloride.html ML786 HYPERLINK https:/www.MedChemE/ml786-dihydrochloride.html HYPERLINK https:/www.MedChemE/ml786-dihydrochloride.html dihydrochlorideCat. No.: HY-14979A HYPERLINK https:/www.MedChemE/Sitravatinib.html Sitravatinib(MGCD516; MG-516) Cat. No.: HY-16961ML786
24、dihydrochloride is a potent and orallybioavailable Raf inhibitor, with IC s of 2.1,504.2, and 2.5 nM for V600EB-Raf, wt B-Raf,and C-Raf, respectively. ML786 dihydrochloridealso inhibits Abl-1, DDR2, EPHA2, KDR, and RET(IC =98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgSitravatinib (MGCD51
25、6) is an orally bioavailablereceptor tyrosine kinase (RTK) inhibitor withIC s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 850nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER,VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1,TRKA, TRKB, respectively.Purity: 99.59%Clinical Data: Phase 3Size: 10 mM 1 mL, 5 mg,
26、10 mg, 25 mg, 50 mg, 100 mg, 200 mg HYPERLINK https:/www.MedChemE/sitravatinib-malate.html Sitravatinib HYPERLINK https:/www.MedChemE/sitravatinib-malate.html HYPERLINK https:/www.MedChemE/sitravatinib-malate.html malate(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A HYPERLINK https:/www.MedChemE/vu6015929.html VU6015929Cat. No.: HY-135401Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with IC s of 1.5 nM
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025版?zhèn)€人車輛抵押債權(quán)債務(wù)處理執(zhí)行協(xié)議3篇
- 2025年度個(gè)人新能源汽車充電站場(chǎng)地承包協(xié)議2篇
- 2025版新能源汽車電池委托加工合同范本3篇
- 2025-2030全球眼科手術(shù)剪行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025年全球及中國(guó)公共交流充電站行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025年全球及中國(guó)碳納米管微球行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025-2030全球汽車燃油回流管路行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 二樓商業(yè)租賃專項(xiàng)協(xié)議(2024版)版
- 二零二五年度車輛牌照租賃市場(chǎng)拓展與合作開發(fā)合同4篇
- 二零二五年度車牌租賃與廣告合作協(xié)議3篇
- 二零二五年度無人駕駛車輛測(cè)試合同免責(zé)協(xié)議書
- 2025年湖北華中科技大學(xué)招聘實(shí)驗(yàn)技術(shù)人員52名歷年高頻重點(diǎn)提升(共500題)附帶答案詳解
- 黑龍江省哈爾濱市2024屆中考數(shù)學(xué)試卷(含答案)
- 高三日語(yǔ)一輪復(fù)習(xí)助詞「と」的用法課件
- 毛渣采購(gòu)合同范例
- 無子女離婚協(xié)議書范文百度網(wǎng)盤
- 2023中華護(hù)理學(xué)會(huì)團(tuán)體標(biāo)準(zhǔn)-注射相關(guān)感染預(yù)防與控制
- 一年級(jí)數(shù)學(xué)個(gè)位數(shù)加減法口算練習(xí)題大全(連加法-連減法-連加減法直接打印版)
- 五年級(jí)上冊(cè)小數(shù)遞等式計(jì)算200道及答案
- 2024年廣東高考政治真題考點(diǎn)分布匯 總- 高考政治一輪復(fù)習(xí)
- 冀教版五年級(jí)下冊(cè)數(shù)學(xué)全冊(cè)教學(xué)課件
評(píng)論
0/150
提交評(píng)論